EZZ Life Science Achieves Robust Quarterly Growth
Company Announcements

EZZ Life Science Achieves Robust Quarterly Growth

EZZ Life Science Holdings Ltd. (AU:EZZ) has released an update.

EZZ Life Science Holdings Ltd. reported substantial growth with customer receipts rising to $23.0m, a 70.3% increase from the previous year, and operating cash flows surged by 120.3% to $4.5 million in Q4 FY24. The company maintained a strong debt-free cash position of $19.0m and continued to reward shareholders by paying a fully franked interim dividend. Additionally, EZZ is expanding globally with new product launches, a significant sales agreement with Pinehills (Hong Kong) Ltd., and securing FDA approval for entry into the US market.

For further insights into AU:EZZ stock, check out TipRanks’ Stock Analysis page.

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App